Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Merck
Harvard Business School
AstraZeneca
Baxter

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Ge Healthcare Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Ge Healthcare
International Patents:116
US Patents:7
Tradenames:61
Ingredients:41
NDAs:53
Drug Master File Entries: 5
Patent Litigation for Ge Healthcare: See patent lawsuits for Ge Healthcare

Drugs and US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare HYPAQUE diatrizoate meglumine INJECTABLE;INJECTION 016403-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare MPI DTPA KIT - CHELATE technetium tc-99m pentetate kit INJECTABLE;INJECTION 017255-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare HYPAQUE diatrizoate meglumine INJECTABLE;INJECTION 016403-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ge Healthcare INDIUM IN 111 OXYQUINOLINE indium in-111 oxyquinoline INJECTABLE;INJECTION 019044-001 Dec 24, 1985 RX Yes Yes   Start Trial   Start Trial
Ge Healthcare HYPAQUE diatrizoate sodium FOR SOLUTION;ORAL, RECTAL 011386-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020808-001 Aug 29, 1997 4,278,654   Start Trial
Ge Healthcare INDIUM IN 111 OXYQUINOLINE indium in-111 oxyquinoline INJECTABLE;INJECTION 019044-001 Dec 24, 1985 4,335,095   Start Trial
Ge Healthcare VISIPAQUE 270 iodixanol INJECTABLE;INJECTION 020808-001 Aug 29, 1997 5,366,722   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993 4,687,659   Start Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007 5,362,475   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Ge Healthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0579826 SPC/GB02/042 United Kingdom   Start Trial PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
0933372 SPC/GB08/018 United Kingdom   Start Trial PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0806968 SPC/GB07/011 United Kingdom   Start Trial PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
1611115 C20150004 00139 Estonia   Start Trial PRODUCT NAME: FLUTEMETAMOOL (18F);REG NO/DATE: EU/1/14/941 26.08.2014
0961612 09C0050 France   Start Trial PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080111
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Colorcon
Moodys
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.